NIH and NCI support for development of novel therapeutics in gynecologic cancer: A user's guide

Lucas Minig, Edward L. Trimble, Michael J. Birrer, Kelly Y. Kim, Naoko Takebe, Jeffrey S. Abrams

Research output: Contribution to journalReview article

Abstract

The development of novel therapeutics is a lengthy and often tortuous process. It frequently spans the identification of new targets, preclinical validation, discovery and refinement of novel therapies, safety studies, phase O, 1, 2, and 3 trials, and reverse translation. NIH and NCI provide via web sites a variety of resources and research tools of great value to investigators. NCI also provides tissue resources useful for discovery and validation, as well as extensive support for preclinical drug development. The NCI's effective partnership with industry and academia, as well as the ongoing NCI-supported clinical trials network, facilitates clinical development of novel therapeutics. Specialized NCI programs focused on cancer imaging, radiation research, and complementary and alternative medicine, also assist the development of novel agents. Finally, the NIH and the NCI sponsor a variety of grant mechanisms, supporting institutions, consortia, and individuals, which investigators seeking to develop novel therapeutics should make themselves familiar.

Original languageEnglish (US)
Pages (from-to)177-180
Number of pages4
JournalGynecologic oncology
Volume116
Issue number2
DOIs
StatePublished - Feb 1 2010
Externally publishedYes

Keywords

  • Grants
  • NIH and NCI resources
  • Novel therapeutics

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'NIH and NCI support for development of novel therapeutics in gynecologic cancer: A user's guide'. Together they form a unique fingerprint.

  • Cite this